John W Babich

List of Publications by Year
in descending order

173 papers	7,548 citations	47 h-index	78 g-index
		47006	66911
176 all docs	176 docs citations	176 times ranked	5971 citing authors

#	Article	IF	Citations
1	Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1280-1292.	6.4	319
2	Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer. Cancer Research, 2009, 69, 6932-6940.	0.9	279
3	First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer. Journal of Nuclear Medicine, 2013, 54, 380-387.	5.0	201
4	Bridging the Gap between in Vitro and in Vivo Imaging:Â Isostructural Re and99mTc Complexes for Correlating Fluorescence and Radioimaging Studies. Journal of the American Chemical Society, 2004, 126, 8598-8599.	13.7	200
5	The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 79S-89S.	5.0	200
6	^{99m}Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2013, 54, 1369-1376.	5.0	193
7	Metabolic Imaging With Î²-Methyl- p -[123 I]-Iodophenyl-Pentadecanoic Acid Identifies Ischemic Memory After Demand Ischemia. Circulation, 2005, 112, 2169-2174.	1.6	191
8	New directions in the coordination chemistry of 99mTc: a reflection on technetium core structures and a strategy for new chelate design. Nuclear Medicine and Biology, 2005, 32, 1-20.	0.6	183
9	Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer. Journal of Medicinal Chemistry, 2008, 51, 7933-7943.	6.4	180
10	Bifunctional Single Amino Acid Chelates for Labeling of Biomolecules with the {Tc(CO)3}+and {Re(CO)3}+Cores. Crystal and Molecular Structures of [ReBr(CO)3(H2NCH2C5H4N)], [Re(CO)3{(C5H4NCH2)2NH}]Br, [Re(CO)3{(C5H4NCH2)2NCH2CO2H}]Br, [Re(CO)3{X(Y)NCH2CO2CH2CH3}]Br (X = Y = 2-pyridylmethyl; X = 2-pyridylmethyl, Y =) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 372 Td (2	4.0	171
11	[ReBr(CO)3{(C5H4NCH2)NH(CH2C4H3S)}], and [Re(CO)3{(C5H4NCH2)N(CH2C4H3S)(CH2CO2)}]. Inorganic An Eighteenâ€Membered Macrocyclic Ligand for Actiniumâ€225 Targeted Alpha Therapy. Angewandte Chemie - International Edition, 2017, 56, 14712-14717.	13.8	163
12	New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clinical Cancer Research, 2016, 22, 9-15.	7.0	155
13	A convenient synthesis, chemical characterization and reactivity of [Re(CO)3(H2O)3]Br: the crystal and molecular structure of [Re(CO)3(CH3CN)2Br]. Inorganic Chemistry Communication, 2004, 7, 1023-1026.	3.9	131
14	^{99m}Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2014, 55, 1791-1798.	5.0	125
15	A New Strategy for the Preparation of Peptide-Targeted Radiopharmaceuticals Based on an Fmoc-Lysine-Derived Single Amino Acid Chelate (SAAC). Automated Solid-Phase Synthesis, NMR Characterization, and in Vitro Screening of fMLF(SAAC)G and fMLF[(SAACâ”Re(CO)3)+]G. Bioconjugate Chemistry, 2004, 15, 128-136.	3.6	112
16	PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. Clinical Cancer Research, 2018, 24, 6300-6307.	7.0	112
17	Glu-Ureidoâ€“Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. Journal of Nuclear Medicine, 2017, 58, 17S-26S.	5.0	111
18	Rapid detection of Parkinson's disease by SPECT with altropane: A selective ligand for dopamine transporters. , 1998, 29, 128-141.		104

#	Article	IF	Citations
19	PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 293-298.	5.0	100
20	Synthesis and Characterization of Organohydrazino Complexes of Technetium, Rhenium, and Molybdenum with the {M(Î·1-HxNNR)(Î·2-HyNNR)} Core and Their Relationship to Radiolabeled Organohydrazine-Derivatized Chemotactic Peptides with Diagnostic Applications. Inorganic Chemistry, 1998, 37, 2701-2716.	4.0	91
21	Targeting prostate cancer: Prostateâ€specific membrane antigen based diagnosis and therapy. Medicinal Research Reviews, 2019, 39, 40-69.	10.5	88
22	Developing the {M(CO)3}+Core for Fluorescence Applications:Â Rhenium Tricarbonyl Core Complexes with Benzimidazole, Quinoline, and Tryptophan Derivatives. Inorganic Chemistry, 2006, 45, 3057-3066.	4.0	79
23	Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1557-1563.	2.2	78
24	¹²³I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy. Journal of Nuclear Medicine, 2011, 52, 1087-1093.	5.0	73
25	Phase I Trial of ⁹⁰Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors. Journal of Nuclear Medicine, 2010, 51, 1524-1531.	5.0	72
26	The Role of Copper in Disulfiram-Induced Toxicity and Radiosensitization of Cancer Cells. Journal of Nuclear Medicine, 2013, 54, 953-960.	5.0	71
27	Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. JCI Insight, 2016, 1, e90064.	5.0	70
28	Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 950-959.	6.4	69
29	The Role of Positron Emission Tomography in Pharmacokinetic Analysis. Drug Metabolism Reviews, 1997, 29, 923-956.	3.6	67
30	Comparison of High-Specific-Activity Ultratrace ^{123/131}I-MIBG and Carrier-Added ^{123/131}I-MIBG on Efficacy, Pharmacokinetics, and Tissue Distribution. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 299-308.	1.0	67
31	Iodofiltic Acid I 123 (BMIPP) Fatty Acid Imaging Improves Initial Diagnosis in Emergency Department Patients With Suspected Acute Coronary Syndromes. Journal of the American College of Cardiology, 2010, 56, 290-299.	2.8	65
32	Dose Escalation Study of No-Carrier-Added ¹³¹I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial. Journal of Nuclear Medicine, 2012, 53, 1155-1163.	5.0	64
33	Phase 2 Study of ^{99m}Tc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection. Journal of Nuclear Medicine, 2017, 58, 1408-1413.	5.0	63
34	Rhenium Tricarbonyl Core Complexes of Thymidine and Uridine Derivatives. Inorganic Chemistry, 2005, 44, 2198-2209.	4.0	62
35	Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1442-1449.	5.0	61
36	Isostructural Re and 99mTc Complexes of Biotin Derivatives for Fluorescence and Radioimaging Studies. Bioconjugate Chemistry, 2006, 17, 590-596.	3.6	60

#	Article	IF	Citations
37	Novel Polar Single Amino Acid Chelates for Technetium-99m Tricarbonyl-Based Radiopharmaceuticals with Enhanced Renal Clearance: Application to Octreotide. Bioconjugate Chemistry, 2010, 21, 1032-1042.	3.6	60
38	Pharmacokinetics of [¹⁸ F]Trovafloxacin in Healthy Human Subjects Studied with Positron Emission Tomography. Antimicrobial Agents and Chemotherapy, 1998, 42, 2048-2054.	3.2	58
39	[11C,127I] Altropane: A highly selective ligand for PET imaging of dopamine transporter sites. Synapse, 2001, 39, 332-342.	1.2	57
40	Thiol- and Thioether-Based Bifunctional Chelates for the {M(CO)3}+Core (M = Tc, Re). Inorganic Chemistry, 2005, 44, 6763-6770.	4.0	57
41	A kit method for the high level synthesis of [211At]MABG. Bioorganic and Medicinal Chemistry, 2007, 15, 3430-3436.	3.0	56
42	Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1841-1851.	6.4	56
43	A Single Dose of ²²⁵Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model. Journal of Nuclear Medicine, 2019, 60, 649-655.	5.0	55
44	The syntheses and structures of â€˜3+2â€™ and â€˜2+2+1â€™ oxorhenium mixed-ligand complexes employing 8-hydroxy-5-nitroquinoline as the bidentate N,O donor ligand. Inorganica Chimica Acta, 2000, 308, 80-90.	2.4	53
45	Radiation Dosimetry, Pharmacokinetics, and Safety of Ultratraceâ„¢ Iobenguane I-131 in Patients with Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 469-475.	1.0	51
46	Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. , 1998, 29, 116-127.		50
47	Isostructural fluorescent and radioactive probes for monitoring neural stem and progenitor cell transplants. Nuclear Medicine and Biology, 2008, 35, 159-169.	0.6	50
48	Rhenium(I) Carbonyl Complexes of 2,4,6-Tris(2-pyridyl)-1,3,5-triazine (TPT). Rhenium(I)-Promoted Methoxylation of the Triazine Ring Carbon Atom in Dinuclear Rhenium Complexes. Inorganic Chemistry, 2001, 40, 2769-2777.	4.0	49
49	Preclinical Evaluation of an 131I-Labeled Benzamide for Targeted Radiotherapy of Metastatic Melanoma. Cancer Research, 2010, 70, 4045-4053.	0.9	48
50	Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide ¹³¹I-BA52. Journal of Nuclear Medicine, 2014, 55, 9-14.	5.0	48
51	Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window. Journal of Nuclear Medicine, 2019, 60, 656-663.	5.0	48
52	Complexes of the fac-{Re(CO)3}+ core with tridentate ligands derived from arylpiperazines. Inorganica Chimica Acta, 2004, 357, 1499-1516.	2.4	47
53	Extension of the Single Amino Acid Chelate Concept (SAAC) to Bifunctional Biotin Analogues for Complexation of the M(CO)3+1 Core (M = Tc and Re):â€‰ Syntheses, Characterization, Biotinidase Stability, and Avidin Binding. Bioconjugate Chemistry, 2006, 17, 579-589.	3.6	45
54	A New Strategy for Preparing Molecular Imaging and Therapy Agents Using Fluorine-Rich (Fluorous) Soluble Supports. Journal of the American Chemical Society, 2006, 128, 3536-3537.	13.7	44

#	Article	IF	Citations
55	Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 647-661.	6.4	44
56	Comprehensive Radiolabeling, Stability, and Tissue Distribution Studies of Technetium-99m Single Amino Acid Chelates (SAAC). Bioconjugate Chemistry, 2009, 20, 1625-1633.	3.6	43
57	Infection imaging with technetium-99m-labeled chemotactic peptide analogs. Seminars in Nuclear Medicine, 1994, 24, 154-168.	4.6	42
58	Comparison of the infection imaging properties of a 99mTc labeled chemotactic peptide with 111In IgG. Nuclear Medicine and Biology, 1995, 22, 643-648.	0.6	42
59	Single amino acid chelate complexes of the M(CO)₃⁺ core for correlating fluorescence and radioimaging studies (Mâ€‰=â€‰^{99m}Tc or Re). Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 255-261.	1.0	42
60	Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement usina a trapped tracer model. European Journal of Nuclear Medicine and Molecular Imaging, 1994, 21, 336-341.	2.1	41
61	Synthesis and structural characterization of rhenium(I) tricarbonyl complexes with the bidentate ligands o-(diphenylphosphino)benzaldehyde (Pâ©O) and o-[(diphenylphosphino)benzylidene]analine (Pâ©N). Inorganica Chimica Acta, 2001, 315, 147-152.	2.4	41
62	Comprehensive Quality Control of the ITG ⁶⁸Ge/⁶⁸Ga Generator and Synthesis of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-PSMA-HBED-CC for Clinical Imaging. Journal of Nuclear Medicine, 2016, 57, 1402-1405.	5.0	41
63	Decreased CSF clearance and increased brain amyloid in Alzheimerâ€™s disease. Fluids and Barriers of the CNS, 2022, 19, 21.	5.0	41
64	Development of a high performance zinc-62/copper-62 radionuclide generator for positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1992, 19, 418-25.	2.1	40
65	Molecular Imaging of Human ACE-1 Expression in Transgenic Rats. JACC: Cardiovascular Imaging, 2012, 5, 409-418.	5.3	39
66	Cationic complexes of the â€˜3+1â€™ oxorheniumâ€“thiolate family. Inorganica Chimica Acta, 2000, 297, 98-105.	2.4	37
67	Altropane, a SPECT or PET imaging probe for dopamine neurons: I. dopamine transporter binding in primate brain. Synapse, 1998, 29, 93-104.	1.2	36
68	Synthesis and characterization of oxorhenium-`3+1' mixed-thiolate complexes. Crystal and molecular structures of [ReO{Î·3-(SCH2CH2)2S}(C6H4X-4-CH2S)] (X=F, Cl, Br, OMe) and of the pendant thiolate compounds [ReO{Î·3-(SCH2CH2)2S}(Î·1-SCH2CH2SCH2CH2SH)] and [ReO{Î·3-(SCH2CH2)2S}{Î·1-SCH2CH(OH)CH(OH)CH2SH}]. Inorganica Chimica Acta, 1999, 284, 252-257.	2.4	36
69	Mapping of local renal blood flow with PET and H(2)(15)O. Journal of Nuclear Medicine, 2002, 43, 470-5.	5.0	36
70	Synthesis, Cytotoxicity, and Insight into the Mode of Action of Re(CO)₃ Thymidine Complexes. ChemMedChem, 2010, 5, 1513-1529.	3.2	35
71	Synthesis and SAR of Novel Re/^{99m}Tc-Labeled Benzenesulfonamide Carbonic Anhydrase IX Inhibitors for Molecular Imaging of Tumor Hypoxia. Journal of Medicinal Chemistry, 2013, 56, 510-520.	6.4	35
72	Quantification of dopamine transporter density in monkeys by dynamic PET imaging of multiple injections of 11C-CFT. , 1996, 24, 262-272.		33

#	Article	IF	Citations
73	99mTc-labeled chemotactic peptides: influence of coligand on distribution of molecular species and infection imaging properties. Synthesis and structural characterization of model complexes with the {Re(Î·2-HNNC5H4N)(Î·1-NNC5H4N)} core. Inorganica Chimica Acta, 2000, 309, 123-136.	2.4	33
74	Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy. Radiation Research, 2015, 184, 482-493.	1.5	33
75	Prostaglandin J2: a potential target for halting inflammationâ€induced neurodegeneration. Annals of the New York Academy of Sciences, 2016, 1363, 125-137.	3.8	33
76	Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: Effects of chelate design on pharmacokinetics. Inorganica Chimica Acta, 2012, 389, 168-175.	2.4	31
77	Intraindividual Comparison of ^{99m}Tc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand ^{99m}Tc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1373-1379.	5.0	31
78	Synthesis and Screening of a Library of Re/Tc-Based Amyloid Probes Derived from Î²-Breaker Peptides. Bioconjugate Chemistry, 2008, 19, 1087-1094.	3.6	30
79	Synthesis and Evaluation of a Series of ^{99m}Tc(CO)₃⁺ Lisinopril Complexes for In Vivo Imaging of Angiotensin-Converting Enzyme Expression. Journal of Nuclear Medicine, 2008, 49, 970-977.	5.0	29
80	18F-labeling and biodistribution of the novel fluoro-quinolone antimicrobial agent, trovafloxacin (CP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	28
81	Schiff base chemistry of the {ReO}3+ core: structural characterization of the unusual â€˜3+2â€™ complex [ReO(Î·3-OC6H4â€“CHî˜…NC6H4-2-S)(Î·2-OC6H4)]. Inorganica Chimica Acta, 2000, 307, 149-153.	2.4	28
82	Synthesis, characterization and crystal structures of mono-, di- and trinuclear rhenium(I) tricarbonyl complexes with 2,3,5,6-tetra(2-pyridyl)pyrazine. Inorganica Chimica Acta, 2001, 315, 66-72.	2.4	28
83	A new bifunctional amino acid chelator targeting the glucose transporter. Inorganica Chimica Acta, 2006, 359, 1603-1612.	2.4	28
84	Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for ⁶⁴Cu/⁶⁷Cu-Based Theranostics in Prostate Cancer. Molecular Pharmaceutics, 2020, 17, 1954-1962.	4.6	28
85	Synthesis of [11C]dapoxetine Â· HCl, a serotonin re-uptake inhibitor: Biodistribution in rat and preliminary PET imaging in the monkey. Nuclear Medicine and Biology, 1994, 21, 669-675.	0.6	27
86	Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of 68 Ga 3+ , 111 In 3+ , 177 Lu 3+ and 225 Ac 3+. Nuclear Medicine and Biology, 2017, 55, 38-46.	0.6	27
87	Spectroscopic and structural studies of complexes of the fac-[Re(Nâˆ©N)(CO)3L]n+ type (Nâˆ©N=2-(2-pyridyl)benzothiazole; L=Cl, Br, CF3SO3â^', CH3CN). Inorganica Chimica Acta, 2001, 314, 91-96.	2.4	26
88	Unusual Reactivity of the {ReVO}3+Core:Â Syntheses and Characterization of Novel Rhenium Halide Complexes withN-Methyl-o-diaminobenzene. Inorganic Chemistry, 2004, 43, 6445-6454.	4.0	26
89	Thermal injury in rats alters glucose utilization by skin, wound, and small intestine, but not by skeletal muscle. Metabolism: Clinical and Experimental, 1996, 45, 1161-1167.	3.4	24
90	Schiff base chemistry of the rhenium(V)-oxo core with â€˜3+2â€™ ligand donor sets. Inorganica Chimica Acta, 2001, 316, 33-40.	2.4	24

#	Article	IF	Citations
91	Synthesis, characterization, and biodistribution of a Technetium-99m â€˜3+1â€™ fatty acid derivative. The crystal and molecular structures of a series of oxorhenium model complexes. Inorganica Chimica Acta, 2002, 338, 149-156.	2.4	24
92	Synthesis and Characterization of Rhenium and Technetium-99m Labeled Insulin. Journal of Medicinal Chemistry, 2010, 53, 2612-2621.	6.4	24
93	Phase I study of ²²⁵Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5015-5015.	1.6	24
94	A New Strategy for the Preparation of Peptide-Targeted Technetium and Rhenium Radiopharmaceuticals. The Automated Solid-Phase Synthesis, Characterization, Labeling, and Screening of a Peptide-Ligand Library Targeted at the Formyl Peptide Receptor. Bioconjugate Chemistry, 2005, 16, 1189-1195.	3.6	23
95	Expansion of the â€˜3 + 1â€™ concept of oxorhenium-thiolate chemistry to cationic and binuclear complexes. Inorganic Chemistry Communication, 1998, 1, 209-212.	3.9	22
96	Exploring oxorhenium â€˜3+1â€™ mixed-ligand complexes carrying the S-benzyl-3-[(2-hydroxyphenyl)methylene]dithiocarbazate [ONS]/monothiol [S] donor set: synthesis and characterization. Inorganica Chimica Acta, 2000, 307, 154-159.	2.4	22
97	Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Toxicity of ¹³¹I-Metaiodobenzylguanidine/Topotecan Combination Therapy to Cells and Xenografts That Express the Noradrenaline Transporter. Journal of Nuclear Medicine, 2012, 53, 1146-1154.	5.0	22
98	Preliminary evaluation of prostate-targeted radiotherapy using 131I-MIP-1095 in combination with radiosensitising chemotherapeutic drugsâ€. Journal of Pharmacy and Pharmacology, 2016, 68, 912-921.	2.4	22
99	Synthesis and characterization of complexes of the {ReO}3+ core with SNS and S donor ligands. Inorganica Chimica Acta, 2000, 306, 30-37.	2.4	21
100	Bifunctional chelates with aliphatic amine donors for labeling of biomolecules with the {Tc(CO) 3 } + and {Re(CO) 3 } + cores: the crystal and molecular structure of [Re(CO) 3 {(H 2 NCH 2 CH 2) 2 N(CH 2) 4 CO 2 Me}]Br. Inorganic Chemistry Communication, 2004, 7, 481-484.	3.9	21
101	Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates. Human Gene Therapy, 2020, 31, 1237-1259.	2.7	21
102	Advances in PSMA theranostics. Translational Oncology, 2022, 22, 101450.	3.7	21
103	Synthesis and biodistribution of 18F-labeled Fleroxacin. Nuclear Medicine and Biology, 1993, 20, 81-87.	0.6	20
104	Triazole Appending Agent (TAAG): A New Synthon for Preparing Iodine-Based Molecular Imaging and Radiotherapy Agents. ACS Medicinal Chemistry Letters, 2012, 3, 313-316.	2.8	20
105	Phase I dose-escalation study of ²²⁵Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, TPS399-TPS399.	1.6	20
106	Synthesis and characterization of oxorhenium(V)â€“â€˜3+1â€™ mixed thiolate [SNS]/[S] and [ONS]/[S] complexes. Crystal and molecular structures of [ReO(Î·3-SCH2C5H3NCH2S)(Î·1-C6H4Br-4-S)], [ReO(Î·3-SCH2C5H3NCH2O)(Î·1-C6H4X-4-S)] (X=Cl, OMe), [ReO(Î·3-SCH2C5H3NCH2O)(Î·1-C6H4OCH3-4-CH2S)] and [ReO(Î·3-SCH2C5H3NCH2S)(Î·1-C5H4NH-2-S)][Cl]. Inorganica Chimica Acta, 2000, 307, 88-96.	2.4	19
107	Phase-1 Clinical Trial Results of High-Specific-Activity Carrier-Free ¹²³I-Iobenguane. Journal of Nuclear Medicine, 2014, 55, 765-771.	5.0	19
108	Pharmacokinetics of 18F-labeled trovafloxacin in normal and Escherichia coli-infected rats and rabbits studied with positron emission tomography. Clinical Microbiology and Infection, 1997, 3, 63-72.	6.0	18

#	Article	IF	Citations
109	{ReIIICl3} Core Complexes with Bifunctional Single Amino Acid Chelates. Inorganic Chemistry, 2002, 41, 5795-5802.	4.0	18
110	N,N-Bis(2-mercaptoethyl)methylamine:â€‰ A New Coligand for Tc-99m Labeling of Hydrazinonicotinamide Peptides. Bioconjugate Chemistry, 2005, 16, 885-902.	3.6	18
111	Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets. Journal of Neuroinflammation, 2018, 15, 272.	7.2	18
112	Rhenium tricarbonyl core complexes with ligands derived from arylpiperazines. The structures of [Re(CO)3{NC5H4CH2N(H)CH2CH2â€“Fphenpip}]Br, [Re(CO)3{(NC5H4CH2)2N(CH2)3â€“CH3OphenpipH}]Br2 and [Re(CO)3{(CH3N2C3H2CH2)(O2CCH2)N(CH2)3â€“CH3OphenpipH2}]BrCl. Inorganic Chemistry Communication, 2003, 6, 1099-1103.	3.9	17
113	Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 114-114.	1.6	17
114	Synthesis of a 11C-labeled NK1 receptor ligand for PET studies. Nuclear Medicine and Biology, 1995, 22, 31-36.	0.6	16
115	Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 538-543.	2.1	16
116	Identification of Ligands and Translation to Clinical Applications. Journal of Nuclear Medicine, 2017, 58, 27S-33S.	5.0	16
117	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296.	2.3	16
118	Bifunctional chelates with mixed aromatic and aliphatic amine donors for labeling of biomolecules with the {Tc(CO)3}+ and {Re(CO)3}+ cores. Inorganica Chimica Acta, 2005, 358, 3691-3700.	2.4	15
119	Novel ether-containing ligands as potential 99mtechnetium(I) heart agents. Inorganic Chemistry Communication, 2007, 10, 1409-1412.	3.9	15
120	A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein-Î± (FAPÎ±). Molecular Imaging and Biology, 2021, 23, 686-696.	2.6	15
121	A suitable time point for quantifying the radiochemical purity of 225Ac-labeled radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 38.	3.9	15
122	Synthesis and biological evaluation of two novel DAT-binding technetium complexes containing a piperidine based analogue of cocaine. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3211-3216.	2.2	14
123	6-Mercaptomethylpyridine-3-carboxylic acid (MEMNIC): a new reagent for peptide labeling with Tc-99m. Inorganica Chimica Acta, 2001, 323, 23-36.	2.4	14
124	Synthesis and validation of fatty acid analogs radiolabeled by nonisotopic substitution. Journal of Nuclear Cardiology, 2007, 14, S100-S109.	2.1	14
125	Oxyaapa: A Picolinate-Based Ligand with Five Oxygen Donors that Strongly Chelates Lanthanides. Inorganic Chemistry, 2020, 59, 5116-5132.	4.0	14
126	A general 11C-labeling approach enabled by fluoride-mediated desilylation of organosilanes. Nature Communications, 2020, 11, 1736.	12.8	14

#	Article	IF	Citations
127	[18F]RPS-544: A PET tracer for imaging the chemokine receptor CXCR4. Nuclear Medicine and Biology, 2018, 60, 37-44.	0.6	13
128	Synthesis and characterization of a â€˜3+2â€™ {Re(V)O}3+ core complex carrying the ONS/PO donor atom set. Inorganica Chimica Acta, 2001, 316, 145-148.	2.4	12
129	Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO. Organic and Biomolecular Chemistry, 2019, 17, 6866-6871.	2.8	12
130	PET Tracers for Imaging Cardiac Function in Cardio-oncology. Current Cardiology Reports, 2022, 24, 247-260.	2.9	12
131	Preoperative imaging of colorectal cancers. Targeting the epithelial membrane antigen with a radiation-labeled monoclonal antibody. Cancer, 1992, 69, 620-625.	4.1	11
132	Complexes of the {ReVOX2}+ (X=Cl, Br) core with single amino acid chelate derivatives. Inorganica Chimica Acta, 2005, 358, 2413-2421.	2.4	11
133	Future directions of myocardial fatty acid imaging. Journal of Nuclear Cardiology, 2007, 14, S153-S163.	2.1	11
134	An unexpected â€˜4+2â€™ [N3S]/[NS] rhenium(IV) complex formed upon cleavage of a Re(V) imido bond. Inorganica Chimica Acta, 2000, 310, 237-241.	2.4	10
135	A convenient solid-phase synthesis methodology for preparing peptide-derived molecular imaging agents Â— Synthesis, characterization, and in vitro screening of Tc(I) Â– chemotactic peptide conjugates. Canadian Journal of Chemistry, 2005, 83, 2060-2066.	1.1	10
136	68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study. Translational Oncology, 2022, 15, 101242.	3.7	10
137	Imaging of focal sites of inflammation in rhesus monkeys with 99mTc-labeled human polyclonal IgG. Nuclear Medicine and Biology, 1994, 21, 111-116.	0.6	9
138	Targeted imaging of infection. Advanced Drug Delivery Reviews, 1999, 37, 237-252.	13.7	9
139	Synthesis and crystal and molecular structure of a tetranuclear cluster based on the rhenium(III)-bisorganohydrazino core: [Re(HNNC4H3N2)(NNC4H3N2)(OCH3)2]4. Inorganica Chimica Acta, 2000, 307, 160-163.	2.4	9
140	Syntheses and structural characterization of rhenium-bis-hydrazinopyrimidine core complexes with thiolate and Schiff base coligands. Inorganica Chimica Acta, 2000, 310, 210-216.	2.4	9
141	An Eighteenâ€Membered Macrocyclic Ligand for Actiniumâ€225 Targeted Alpha Therapy. Angewandte Chemie, 2017, 129, 14904-14909.	2.0	9
142	66Ga: A Novelty or a Valuable Preclinical Screening Tool for the Design of Targeted Radiopharmaceuticals?. Molecules, 2018, 23, 2575.	3.8	9
143	Otto: a 4.04â€‰GBq (109â€‰mCi) 68Ge/68Ga generator, first of its kind - extended quality control and performance evaluation in the clinical production of [68Ga]Ga-PSMA-11. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 5.	3.9	9
144	Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 5560-5560.	1.6	9

#	Article	IF	Citations
145	Structural characterizations of an Re(IV) complex [ReCl4(OPPh3)2] and of an imino species [ReOCl2(PPh3)(Î·2-OC6H4-2-CHî...NH)] prepared from the reaction of [ReOCl3(PPh3)2] with salicylaldoxime. Inorganica Chimica Acta, 2000, 306, 112-115.	2.4	8
146	Continuation of comprehensive quality control of the itG 68 Ge/ 68 Ga generator and production of 68 Ga-DOTATOC and 68 Ga-PSMA-HBED-CC for clinical research studies. Nuclear Medicine and Biology, 2017, 53, 37-39.	0.6	8
147	[18F]Fluoroethyltriazolyl Monocyclam Derivatives as Imaging Probes for the Chemokine Receptor CXCR4. Molecules, 2019, 24, 1612.	3.8	8
148	ï»¿Preclinical evaluation of peptide-based radiotracers for integrin Î±vÎ²6-positive pancreatic carcinoma. Nuklearmedizin - NuclearMedicine, 2019, 58, 309-318.	0.7	8
149	An evaluation of99mTc-HMPAO uptake in cerebral gliomas ?a comparison with X-ray CT. European Journal of Nuclear Medicine and Molecular Imaging, 1990, 16, 293-298.	2.1	7
150	Direct Reductive Alkylation of Amino Acids: Synthesis of Bifunctional Chelates for Nuclear Imaging. Synthesis, 2004, 2004, 1759-1766.	2.3	7
151	Synthesis of [11C]palmitic acid for PET imaging using a single molecular sieve 13X cartridge for reagent trapping, radiolabeling and selective purification. Nuclear Medicine and Biology, 2015, 42, 685-690.	0.6	7
152	In Vivo Imaging of Fibroblast Activity Using a 68Ga-Labeled Fibroblast Activation Protein Alpha (FAP-Î±) Inhibitor. Journal of Bone and Joint Surgery - Series A, 2021, 103, e40.	3.0	7
153	Synthesis and structural characterization of the neutral indium (III) thiolate species In{(SCH2CH2)3N}. Inorganic Chemistry Communication, 1998, 1, 164-166.	3.9	6
154	Investigations of the {ReO}3+ core: A â€˜2+2â€™ complex from bidentate and potentially trident ligands: [ReO(Î·2-HOC6H4-2-CH2NC6H4S)(Î·2-SC5H4N)(PPh3)]. Inorganica Chimica Acta, 2000, 306, 38-41.	2.4	6
155	Differential in radiosensitizing potency of enantiomers of the fatty acid synthase inhibitor C75. Chirality, 2017, 29, 10-13.	2.6	6
156	3D-printed automation for optimized PET radiochemistry. Science Advances, 2019, 5, eaax4762.	10.3	6
157	Population-based input function for TSPO quantification and kinetic modeling with [11C]-DPA-713. EJNMMI Physics, 2021, 8, 39.	2.7	6
158	Defining the origins of multiple emission/excitation in rhenium-bisthiazole complexes. Inorganica Chimica Acta, 2019, 489, 301-309.	2.4	4
159	Novel monoamine transporter ligands reduce cocaine-induced enhancement of brain stimulation reward. Pharmacology Biochemistry and Behavior, 2001, 68, 171-180.	2.9	3
160	Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC).. Journal of Clinical Oncology, 2012, 30, 173-173.	1.6	3
161	Impact of elution impurities on DOTA and NOTA labeling with two commercial 68Ge/68Ga generators. Journal of Radioanalytical and Nuclear Chemistry, 2018, 317, 1485-1490.	1.5	2
162	Synthesis of [1â€“11C]Butanol via a facile solid phase extraction protocol. Applied Radiation and Isotopes, 2020, 159, 109078.	1.5	2

#	Article	IF	Citations
163	A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, TPS188-TPS188.	1.6	2
164	Positron Emission Tomography: Clinical Applications and Pharmaceutical Care. Journal of Pharmacy Practice, 1994, 7, 124-139.	1.0	1
165	Synthesis of 2-[18F]Fluoro-2-deoxy-l-dlucose and positron emission tomography studies in monkeys. Nuclear Medicine and Biology, 1994, 21, 633-640.	0.6	1
166	Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.. Journal of Clinical Oncology, 2021, 39, 120-120.	1.6	1
167	Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, TPS339-TPS339.	1.6	1
168	Feasibility of Population-Based Input Function for Kinetic Analysis of [¹¹C]-DPA-713. , 2020, , .		1
169	One Year Follow-Up for the Phase I MTD Study of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma (Pheo). Pancreas, 2010, 39, 272.	1.1	0
170	501. Radioiodinated Adeno-Associated Virus: A Promising New Approach for Monitoring Gene Therapy. Molecular Therapy, 2015, 23, S200.	8.2	0
171	Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, TPS5093-TPS5093.	1.6	0
172	Physical Performance of SynchroPET ArterialPETâ„¢, a Human Wrist PET Prototype Scanner for Non-Invasive Arterial Input Function Evaluation. , 2020, , .		0
173	Synthesis and Evaluation of 11C-Labeled Triazolones as Probes for Imaging Fatty Acid Synthase Expression by Positron Emission Tomography. Molecules, 2022, 27, 1552.	3.8	0